Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) position statements on polymyxin B and colistin clinical breakpoints.

Satlin MJ, Lewis JS, Weinstein MP, Patel J, Humphries RM, Kahlmeter G, Giske CG, Turnidge J.

Clin Infect Dis. 2020 Feb 13. pii: ciaa121. doi: 10.1093/cid/ciaa121. [Epub ahead of print]

PMID:
32052041
2.

Isothermal microcalorimetry minimal inhibitory concentration testing in extensively drug resistant Gram-negative bacilli - A multicenter study.

Tellapragda C, Hasan B, Antonelli A, Maruri A, de Vogel C, Gijón D, Coppi M, Verbon A, van Wamel W, Rossolini GM, Cantón R, Giske CG.

Clin Microbiol Infect. 2020 Jan 29. pii: S1198-743X(20)30051-3. doi: 10.1016/j.cmi.2020.01.026. [Epub ahead of print]

3.

Reply from Kahlmeter and Giske to Brecher, 'EUCAST and CLSI Point-Counterpoint on Susceptibility Breakpoints: Do Two "I Agree"s Miss the Point?'

Kahlmeter G, Giske CG.

J Clin Microbiol. 2019 Dec 23;58(1). pii: e01519-19. doi: 10.1128/JCM.01519-19. Print 2019 Dec 23. No abstract available.

PMID:
31871059
4.

Effects of the Antimicrobial Peptide LL-37 and Innate Effector Mechanisms in Colistin-Resistant Klebsiella pneumoniae With mgrB Insertions.

Al-Farsi HM, Al-Adwani S, Ahmed S, Vogt C, Ambikan AT, Leber A, Al-Jardani A, Al-Azri S, Al-Muharmi Z, Toprak MS, Giske CG, Bergman P.

Front Microbiol. 2019 Nov 14;10:2632. doi: 10.3389/fmicb.2019.02632. eCollection 2019.

5.

Risk factors for mortality among patients with Pseudomonas aeruginosa bacteraemia: a retrospective multicentre study.

Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, Rivera A, Pulcini C, Fattah MA, Haquin J, MacGowan A, Grier S, Chazan B, Yanovskay A, Ami RB, Landes M, Nesher L, Zaidman-Shimshovitz A, McCarthy K, Paterson DL, Tacconelli E, Buhl M, Maurer S, Rodriguez-Bano J, Morales I, Oliver A, de Gopegui ER, Cano A, Machuca I, Gozalo-Marguello M, Martinez-Martinez L, Gonzalez-Barbera EM, Alfaro IG, Salavert M, Beovic B, Saje A, Mueller-Premru M, Pagani L, Vitrat V, Kofteridis D, Zacharioudaki M, Maraki S, Weissman Y, Paul M, Dickstein Y, Leibovici L, Yahav D.

Int J Antimicrob Agents. 2020 Feb;55(2):105847. doi: 10.1016/j.ijantimicag.2019.11.004. Epub 2019 Nov 23.

PMID:
31770625
6.

Risk for Endocarditis in Bacteremia With Streptococcus-Like Bacteria: A Retrospective Population-Based Cohort Study.

Berge A, Kronberg K, Sunnerhagen T, Nilson BHK, Giske CG, Rasmussen M.

Open Forum Infect Dis. 2019 Oct 4;6(10):ofz437. doi: 10.1093/ofid/ofz437. eCollection 2019 Oct.

7.

Klebsiella pneumoniae Expressing VIM-1 Metallo-β-Lactamase Is Resensitized to Cefotaxime via Thiol-Mediated Zinc Chelation.

Karadottir H, Coorens M, Liu Z, Wang Y, Agerberth B, Giske CG, Bergman P.

Infect Immun. 2019 Dec 17;88(1). pii: e00756-19. doi: 10.1128/IAI.00756-19. Print 2019 Dec 17.

PMID:
31611270
8.

Penicillin V four times daily for five days versus three times daily for 10 days in patients with pharyngotonsillitis caused by group A streptococci: randomised controlled, open label, non-inferiority study.

Skoog Ståhlgren G, Tyrstrup M, Edlund C, Giske CG, Mölstad S, Norman C, Rystedt K, Sundvall PD, Hedin K.

BMJ. 2019 Oct 4;367:l5337. doi: 10.1136/bmj.l5337.

9.

Strong correlation between the rates of intrinsically antibiotic-resistant species and the rates of acquired resistance in Gram-negative species causing bacteraemia, EU/EEA, 2016.

Jarlier V, Diaz Högberg L, Heuer OE, Campos J, Eckmanns T, Giske CG, Grundmann H, Johnson AP, Kahlmeter G, Monen J, Pantosti A, Rossolini GM, van de Sande-Bruinsma N, Vatopoulos A, Żabicka D, Žemličková H, Monnet DL, Simonsen GS; Ears-Net Participants.

Euro Surveill. 2019 Aug;24(33). doi: 10.2807/1560-7917.ES.2019.24.33.1800538.

10.

Ceftazidime, carbapenems, or piperacillin-tazobactam as single definitive therapy for Pseudomonas aeruginosa bloodstream infection - a multi-site retrospective study.

Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, Rivera A, Pulcini C, Abdel Fattah M, Haquin J, Macgowan A, Grier S, Gibbs J, Chazan B, Yanovskay A, Ben Ami R, Landes M, Nesher L, Zaidman-Shimshovitz A, McCarthy K, Paterson DL, Tacconelli E, Buhl M, Mauer S, Bano JR, Morales I, Oliver A, Ruiz de Gopegui E, Cano A, Machuca I, Gozalo-Marguello M, Martinez LM, Gonzalez-Barbera EM, Alfaro IG, Salavert M, Beovic B, Saje A, Mueller-Premru M, Pagani L, Vitrat V, Kofteridis D, Zacharioudaki M, Maraki S, Weissman Y, Paul M, Dickstein Y, Leibovici L, Yahav D.

Clin Infect Dis. 2019 Jul 17. pii: ciz668. doi: 10.1093/cid/ciz668. [Epub ahead of print]

PMID:
31323088
11.
12.
13.

Optical DNA Mapping Combined with Cas9-Targeted Resistance Gene Identification for Rapid Tracking of Resistance Plasmids in a Neonatal Intensive Care Unit Outbreak.

Bikkarolla SK, Nordberg V, Rajer F, Müller V, Kabir MH, Kk S, Dvirnas A, Ambjörnsson T, Giske CG, Navér L, Sandegren L, Westerlund F.

mBio. 2019 Jul 9;10(4). pii: e00347-19. doi: 10.1128/mBio.00347-19.

14.

Transmission events and antimicrobial susceptibilities of methicillin-resistant Staphylococcus argenteus in Stockholm.

Giske CG, Dyrkell F, Arnellos D, Vestberg N, Hermansson Panna S, Fröding I, Ullberg M, Fang H.

Clin Microbiol Infect. 2019 Oct;25(10):1289.e5-1289.e8. doi: 10.1016/j.cmi.2019.06.003. Epub 2019 Jun 20.

PMID:
31229597
15.

Lyme neuroborreliosis epidemiology in Sweden 2010 to 2014: clinical microbiology laboratories are a better data source than the hospital discharge diagnosis register.

Dahl V, Wisell KT, Giske CG, Tegnell A, Wallensten A.

Euro Surveill. 2019 May;24(20). doi: 10.2807/1560-7917.ES.2019.24.20.1800453.

16.

Risk factors for community-onset bloodstream infection with extended-spectrum β-lactamase-producing Enterobacteriaceae: national population-based case-control study.

Isendahl J, Giske CG, Tegmark Wisell K, Ternhag A, Nauclér P.

Clin Microbiol Infect. 2019 Nov;25(11):1408-1414. doi: 10.1016/j.cmi.2019.04.002. Epub 2019 Apr 13.

PMID:
30986557
17.

Prediction of bloodstream infection caused by extended-spectrum β-lactamase-producing Enterobacterales in patients with suspected community-onset sepsis.

Fröding I, Valik JK, Bolinder L, Nauclér P, Giske CG.

Int J Antimicrob Agents. 2019 Jun;53(6):820-829. doi: 10.1016/j.ijantimicag.2019.02.008. Epub 2019 Feb 16.

PMID:
30779954
18.

Dynamics of Resistance Plasmids in Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae during Postinfection Colonization.

Brolund A, Rajer F, Giske CG, Melefors Ö, Titelman E, Sandegren L.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02201-18. doi: 10.1128/AAC.02201-18. Print 2019 Apr.

19.

Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.

Forsman LD, Jonsson J, Wagrell C, Werngren J, Mansjö M, Wijkander M, Groenheit R, Hammar U, Giske CG, Schön T, Bruchfeld J.

Clin Infect Dis. 2019 Sep 27;69(8):1394-1402. doi: 10.1093/cid/ciy1068.

PMID:
30561569
20.

USA300 methicillin-resistant Staphylococcus aureus in Stockholm, Sweden, from 2008 to 2016.

Enström J, Fröding I, Giske CG, Ininbergs K, Bai X, Sandh G, Tollström UB, Ullberg M, Fang H.

PLoS One. 2018 Nov 7;13(11):e0205761. doi: 10.1371/journal.pone.0205761. eCollection 2018.

21.

Performance of the EUCAST disc diffusion method and two MIC methods in detection of Enterobacteriaceae with reduced susceptibility to meropenem: the NordicAST CPE study.

Haldorsen B, Giske CG, Hansen DS, Orri Helgason K, Kahlmeter G, Löhr IH, Matuschek E, Österblad M, Rantakokko-Jalava K, Wang M, Småbrekke L, Samuelsen Ø, Sundsfjord A.

J Antimicrob Chemother. 2018 Oct 1;73(10):2905. doi: 10.1093/jac/dky339. No abstract available.

22.

Performance of the EUCAST disc diffusion method and two MIC methods in detection of Enterobacteriaceae with reduced susceptibility to meropenem: the NordicAST CPE study.

Haldorsen B, Giske CG, Hansen DS, Helgason KO, Kahlmeter G, Löhr IH, Matuschek E, Österblad M, Rantakokko-Jalava K, Wang M, Småbrekke L, Samuelsen Ø, Sundsfjord A; NordicAST CPE Study Group.

J Antimicrob Chemother. 2018 Oct 1;73(10):2738-2747. doi: 10.1093/jac/dky276. Erratum in: J Antimicrob Chemother. 2018 Oct 1;73(10):2905.

23.

Temporal Dynamics and Risk Factors for Bloodstream Infection With Extended-spectrum β-Lactamase-producing Bacteria in Previously-colonized Individuals: National Population-based Cohort Study.

Isendahl J, Giske CG, Hammar U, Sparen P, Tegmark Wisell K, Ternhag A, Nauclér P.

Clin Infect Dis. 2019 Feb 1;68(4):641-649. doi: 10.1093/cid/ciy539.

PMID:
29961883
24.

Infection with high proportion of multidrug-resistant bacteria in conflict-related injuries is associated with poor outcomes and excess resource consumption: a cohort study of Syrian patients treated in Jordan.

Älgå A, Wong S, Shoaib M, Lundgren K, Giske CG, von Schreeb J, Malmstedt J.

BMC Infect Dis. 2018 May 22;18(1):233. doi: 10.1186/s12879-018-3149-y.

25.

Invasive infection caused by Klebsiella pneumoniae is a disease affecting patients with high comorbidity and associated with high long-term mortality.

Vading M, Nauclér P, Kalin M, Giske CG.

PLoS One. 2018 Apr 6;13(4):e0195258. doi: 10.1371/journal.pone.0195258. eCollection 2018.

26.

Molecular epidemiology of NDM-1- and OXA-48-producing Klebsiella pneumoniae in an Iranian hospital: clonal dissemination of ST11 and ST893.

Solgi H, Badmasti F, Giske CG, Aghamohammad S, Shahcheraghi F.

J Antimicrob Chemother. 2018 Jun 1;73(6):1517-1524. doi: 10.1093/jac/dky081.

PMID:
29518198
27.

Introduction of a hydrolysis probe PCR assay for high-throughput screening of methicillin-resistant Staphylococcus aureus with the ability to include or exclude detection of Staphylococcus argenteus.

Bogestam K, Vondracek M, Karlsson M, Fang H, Giske CG.

PLoS One. 2018 Feb 9;13(2):e0192782. doi: 10.1371/journal.pone.0192782. eCollection 2018.

28.

Neonatal intestinal colonization with extended-spectrum β-lactamase-producing Enterobacteriaceae-a 5-year follow-up study.

Nordberg V, Jonsson K, Giske CG, Iversen A, Aspevall O, Jonsson B, Camporeale A, Norman M, Navér L.

Clin Microbiol Infect. 2018 Sep;24(9):1004-1009. doi: 10.1016/j.cmi.2017.12.028. Epub 2018 Jan 8.

29.

MIC-based dose adjustment: facts and fables.

Mouton JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge J.

J Antimicrob Chemother. 2018 Mar 1;73(3):564-568. doi: 10.1093/jac/dkx427.

PMID:
29216348
30.

Colistin antimicrobial susceptibility testing-can the slow and challenging be replaced by the rapid and convenient?

Giske CG, Kahlmeter G.

Clin Microbiol Infect. 2018 Feb;24(2):93-94. doi: 10.1016/j.cmi.2017.10.007. Epub 2017 Oct 21. No abstract available.

31.

Emergence of carbapenem resistant Escherichia coli isolates producing blaNDM and blaOXA-48-like carried on IncA/C and IncL/M plasmids at two Iranian university hospitals.

Solgi H, Giske CG, Badmasti F, Aghamohammad S, Havaei SA, Sabeti S, Mostafavizadeh K, Shahcheraghi F.

Infect Genet Evol. 2017 Nov;55:318-323. doi: 10.1016/j.meegid.2017.10.003. Epub 2017 Oct 4.

PMID:
28987805
32.

Molecular characterization of intestinal carriage of carbapenem-resistant Enterobacteriaceae among inpatients at two Iranian university hospitals: first report of co-production of bla NDM-7 and bla OXA-48.

Solgi H, Badmasti F, Aminzadeh Z, Giske CG, Pourahmad M, Vaziri F, Havaei SA, Shahcheraghi F.

Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2127-2135. doi: 10.1007/s10096-017-3035-3. Epub 2017 Jun 21.

PMID:
28639165
33.

Escherichia coli: an old friend with new tidings.

Vila J, Sáez-López E, Johnson JR, Römling U, Dobrindt U, Cantón R, Giske CG, Naas T, Carattoli A, Martínez-Medina M, Bosch J, Retamar P, Rodríguez-Baño J, Baquero F, Soto SM.

FEMS Microbiol Rev. 2016 Jul 1;40(4):437-463. doi: 10.1093/femsre/fuw005. Review.

34.
35.

Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study.

Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, Cantón R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Monnet DL; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group.

Lancet Infect Dis. 2017 Feb;17(2):153-163. doi: 10.1016/S1473-3099(16)30257-2. Epub 2016 Nov 18.

PMID:
27866944
36.

14-Year Survey in a Swedish County Reveals a Pronounced Increase in Bloodstream Infections (BSI). Comorbidity - An Independent Risk Factor for Both BSI and Mortality.

Holmbom M, Giske CG, Fredrikson M, Östholm Balkhed Å, Claesson C, Nilsson LE, Hoffmann M, Hanberger H.

PLoS One. 2016 Nov 11;11(11):e0166527. doi: 10.1371/journal.pone.0166527. eCollection 2016.

37.

Community carriage of ESBL-producing Escherichia coli is associated with strains of low pathogenicity: a Swedish nationwide study.

Ny S, Löfmark S, Börjesson S, Englund S, Ringman M, Bergström J, Nauclér P, Giske CG, Byfors S.

J Antimicrob Chemother. 2017 Feb;72(2):582-588. doi: 10.1093/jac/dkw419. Epub 2016 Oct 24.

PMID:
27798205
38.

Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients.

Petersson J, Giske CG, Eliasson E.

Acta Anaesthesiol Scand. 2016 Nov;60(10):1425-1436. doi: 10.1111/aas.12808. Epub 2016 Sep 21.

PMID:
27655029
39.

A randomized controlled study of 5 and 10 days treatment with phenoxymethylpenicillin for pharyngotonsillitis caused by streptococcus group A - a protocol study.

Skoog G, Edlund C, Giske CG, Mölstad S, Norman C, Sundvall PD, Hedin K.

BMC Infect Dis. 2016 Sep 13;16:484. doi: 10.1186/s12879-016-1813-7.

40.

Frequent acquisition of low-virulence strains of ESBL-producing Escherichia coli in travellers.

Vading M, Kabir MH, Kalin M, Iversen A, Wiklund S, Nauclér P, Giske CG.

J Antimicrob Chemother. 2016 Dec;71(12):3548-3555. Epub 2016 Aug 26.

PMID:
27566312
41.

The IRIDICA PCR/Electrospray Ionization-Mass Spectrometry Assay on Bronchoalveolar Lavage for Bacterial Etiology in Mechanically Ventilated Patients with Suspected Pneumonia.

Strålin K, Ehn F, Giske CG, Ullberg M, Hedlund J, Petersson J, Spindler C, Özenci V.

PLoS One. 2016 Jul 27;11(7):e0159694. doi: 10.1371/journal.pone.0159694. eCollection 2016.

42.

Evaluation of antibacterial activities of colistin, rifampicin and meropenem combinations against NDM-1-producing Klebsiella pneumoniae in 24 h in vitro time-kill experiments.

Lagerbäck P, Khine WW, Giske CG, Tängdén T.

J Antimicrob Chemother. 2016 Aug;71(8):2321-5. doi: 10.1093/jac/dkw213. Epub 2016 Jun 21.

PMID:
27334665
43.

Etiology of bone and joint infections: a case series of 363 consecutive patients from an orthopaedic infection unit.

Wallander K, Jorup-Rönström C, Ullberg M, Törnblom I, Ottosson C, Giske CG.

Infect Dis (Lond). 2016 Aug;48(8):618-25. doi: 10.1080/23744235.2016.1183814. Epub 2016 May 17.

PMID:
27187631
44.

Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Davies Forsman L, Giske CG, Bruchfeld J, Schön T, Juréen P, Ängeby K.

Int J Mycobacteriol. 2015 Mar;4 Suppl 1:80-1. doi: 10.1016/j.ijmyco.2014.10.018. Epub 2014 Nov 11.

45.

Metagenomic analysis of bloodstream infections in patients with acute leukemia and therapy-induced neutropenia.

Gyarmati P, Kjellander C, Aust C, Song Y, Öhrmalm L, Giske CG.

Sci Rep. 2016 Mar 21;6:23532. doi: 10.1038/srep23532.

46.

Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study.

Kjellander C, Björkholm M, Källman O, Giske CG, Weibull CE, Löve TJ, Landgren O, Kristinsson SY.

Ann Hematol. 2016 May;95(6):871-9. doi: 10.1007/s00277-016-2643-9. Epub 2016 Mar 15.

PMID:
26976017
47.

A two-centre evaluation of RAPIDEC® CARBA NP for carbapenemase detection in Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp.

Kabir MH, Meunier D, Hopkins KL, Giske CG, Woodford N.

J Antimicrob Chemother. 2016 May;71(5):1213-6. doi: 10.1093/jac/dkv468. Epub 2016 Jan 13.

PMID:
26769895
48.

Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.

Niward K, Ängeby K, Chryssanthou E, Paues J, Bruchfeld J, Jureen P, Giske CG, Kahlmeter G, Schön T.

J Antimicrob Chemother. 2016 Feb;71(2):333-8. doi: 10.1093/jac/dkv353. Epub 2015 Nov 3.

PMID:
26538509
49.

Successful international clones of blaCTX-M-15-producing Klebsiella pneumoniae with coexpression of plasmid-mediated quinolone resistance (PMQR) determinants in Tehran hospitals.

Nematzadeh S, Shahcheraghi F, Iversen A, Giske CG.

Diagn Microbiol Infect Dis. 2015 Dec;83(4):371-4. doi: 10.1016/j.diagmicrobio.2015.09.005. Epub 2015 Sep 11.

PMID:
26458278
50.

Bacterial Landscape of Bloodstream Infections in Neutropenic Patients via High Throughput Sequencing.

Gyarmati P, Kjellander C, Aust C, Kalin M, Öhrmalm L, Giske CG.

PLoS One. 2015 Aug 13;10(8):e0135756. doi: 10.1371/journal.pone.0135756. eCollection 2015.

Supplemental Content

Loading ...
Support Center